SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis

Medicine & Life Sciences

• SF 1126 100%
• B-Cell Lymphoma 47%
• Phosphatidylinositol 3-Kinases 45%
• Cell Cycle Checkpoints 44%
• Non-Hodgkin's Lymphoma 43%
• Apoptosis 27%
• idelalisib 16%
• Cell Proliferation 13%
• Rituximab 11%
• Cell Line 9%
• B-Lymphocytes 7%
• arginyl-glycyl-aspartic acid 7%
• Glycogen Synthase Kinase 3 6%
• G1 Phase Cell Cycle Checkpoints 6%
• 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 6%
• Prodrugs 5%
• Cyclin D1 5%
• Neoplasms 4%
• Lymphoma 4%
• Leukemia 4%
• Cell Cycle 4%
• Phosphorylation 3%
• Clinical Trials 3%
• Survival 2%
• Growth 2%
• In Vitro Techniques 2%
• Therapeutics 1%